Close Menu

Precision Oncology News: Breaking News

The companies hope to combine their technologies to provide pharmaceutical customers with an end-to-end workflow for multiplex histological staining and imaging. 

Qualigen Therapeutics will acquire intellectual property rights to the family of RAS-targeting small molecules and pay royalties to Louisville upon commercialization.

The multi-year collaboration will study a lung and breast cancer drug in adaptive Phase II trials, which will allow for the exploration of biomarkers of response and resistance.

The updated guidelines now also highlight the use of PCR and next-generation sequencing to determine microsatellite instability. 

Within the partnership, Strata Oncology will use its StrataNGS test to identify patients with NRG1 gene fusions who may be eligible to enroll in a Phase II trial for the drug.

The Phase II trial in China will enroll 106 NSCLC patients with ROS1 fusions who have either never received a tyrosine kinase inhibitor or have received Xalkori.

GenPro will use its EpiMarker machine-learning platform to identify a network of genomic DNA methylation sites in patients' circulating immune cells that may be predictive of drug response.